StockData
Editas Medicine, Inc. logo

Editas Medicine, Inc. (EDIT) stock

EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/309% above fair value
$1.82−0.05 (-2.41%)

Close on Nov 17, 2026Market cap $280.28MP/E –Yield –

Editas Medicine price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Editas Medicine's price to sales ratio was 5.0× on Nov 11, 2026, against 4.8× a year earlier. Over the last 5 years it ranged from 1.7× to 74.1×, with a median of 7.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20265.0×+0.8
2025Dec 31, 20254.1×+2.4
2024Dec 31, 20241.7×−31.9
2023Dec 29, 202333.6×+9.8
2022Dec 30, 202223.8×−50.3
2021Dec 31, 202174.1×+26.5
2020Dec 31, 202047.6×−57.7
2019Dec 31, 2019105.3×+68.6
2018Dec 31, 201836.7×–

More Editas Medicine figures

See a number that looks wrong?